dengu
viru
denv
caus
agent
dengu
fever
dengu
hemorrhag
fever
viru
endem
countri
caus
million
infect
per
year
dengu
vaccin
develop
challeng
need
induc
simultan
protect
four
antigen
distinct
denv
serotyp
evid
condit
vaccin
enhanc
diseas
due
specif
immun
viru
sever
liveattenu
tetraval
dengu
viru
vaccin
display
partial
efficaci
challeng
induc
balanc
protect
immun
serotyp
instead
use
wholeviru
formul
explor
potenti
particul
subunit
vaccin
base
denv
eprotein
display
nanoparticl
precis
mold
use
particl
replic
nonwet
templat
print
technolog
describ
immun
studi
vaccin
candid
ectodomain
protein
express
secret
recombin
protein
srece
purifi
adsorb
poli
lacticcoglycol
acid
plga
nanoparticl
differ
size
shape
show
print
nanoparticl
adsorb
srece
without
adjuv
induc
higher
igg
titer
potent
neutral
antibodi
respons
compar
solubl
srece
protein
alon
antigen
traffick
indic
print
nanoparticl
display
srece
prolong
bioavail
antigen
drain
lymph
node
creat
antigen
depot
result
demonstr
print
nanoparticl
promis
platform
deliv
subunit
vaccin
flavivirus
dengu
zika
dengu
viru
denv
transmit
mosquito
endem
countri
caus
million
infect
yearli
infect
clinic
unappar
specif
condit
dengu
caus
sever
lethal
diseas
denv
distinct
serotyp
secondari
denv
infect
associ
hemorrhag
fever
dengu
shock
syndrom
enhanc
infect
complic
vaccin
develop
make
necessari
induc
protect
immun
serotyp
sinc
whole
viru
vaccin
candid
struggl
induc
protect
immun
develop
nanoparticl
display
vaccin
approach
express
purifi
character
solubl
recombin
eprotein
srece
regardless
nanoparticl
shape
size
particul
srece
enhanc
denv
specif
igg
titer
induc
robust
long
last
neutral
antibodi
respons
adsorb
srece
nanoparticl
prolong
exposur
srece
immun
system
nanoparticl
display
show
great
promis
dengu
vaccin
develop
possibl
mosquitoborn
virus
like
zika
viru
nanoparticl
deliveri
dengu
vaccin
plo
neglect
tropic
diseas
dengu
viru
denv
member
flavivirida
famili
caus
agent
dengu
fever
dengu
hemorrhag
fever
denv
aed
sp
mosquito
vector
wide
distribut
tropic
subtrop
region
preval
arthropod
born
viral
pathogen
worldwid
approxim
half
world
popul
risk
infect
result
million
report
case
infect
yearli
roughli
million
infect
develop
sever
diseas
nearli
fatal
countri
endem
denv
geograph
expans
expect
increas
due
climat
chang
global
travel
trade
viral
evolut
addit
dengu
complex
diseas
result
wide
varieti
clinic
symptom
major
infect
mild
clinic
appar
infect
often
misdiagnos
due
similar
preval
tropic
diseas
symptom
present
patient
undergo
sudden
onset
fever
remain
day
accompani
arthralgia
myalgia
skin
rash
dengu
viru
complex
consist
distinct
serotyp
design
primari
infect
induc
longterm
protect
immun
serotyp
infect
individu
suscept
secondari
infect
new
serotyp
secondari
heterotyp
infect
associ
sever
potenti
fatal
dengu
hemorrhag
fever
dengu
shock
syndrom
protect
immun
one
serotyp
may
increas
risk
diseas
upon
exposur
serotyp
lead
dengu
vaccin
base
tetraval
formul
induc
simultan
immun
serotyp
sever
vaccin
platform
current
preclin
clinic
develop
includ
live
attenu
viru
vaccin
live
chimer
vaccin
inactiv
viru
formul
recombin
viru
vaccin
dna
subunit
vaccin
live
viru
formul
progress
clinic
trial
lead
candid
test
two
larg
efficaci
studi
demonstr
partial
efficaci
vari
serotyp
base
prior
dengu
exposur
histori
individu
moreov
popul
vaccin
appear
transient
increas
risk
diseas
peopl
expos
natur
infect
recent
advanc
molecular
biolog
shown
safeti
potenti
ration
design
vaccin
candid
move
away
whole
viru
paradigm
direct
vaccinolog
toward
subunit
vaccin
formul
subunit
approach
dengu
gener
involv
exploit
eprotein
major
immunogen
even
though
sever
proteinbas
subunit
vaccin
approach
appear
immunogen
effect
small
anim
model
gener
immunogen
primat
induct
efficaci
protect
immun
respons
reli
proper
antigen
present
antigen
present
cell
apc
includ
b
cell
dendrit
cell
dc
macrophag
directli
associ
product
antibodi
activ
tlymphocyt
induc
adapt
immun
lead
protect
immunolog
memori
gener
subunit
antigen
vaccin
candid
poorli
effect
vaccin
candid
due
size
degrad
nonspecif
target
lack
crosspresent
poor
uptak
apc
coat
solubl
antigen
carrier
effect
strategi
increas
immunogen
weak
immunogen
past
decad
control
releas
prophylact
antigen
achiev
use
nanoparticl
vehicl
carrier
compos
biodegrad
polym
one
promis
aspect
coat
subunit
peptid
nanoparticl
carrier
potenti
mimic
structur
immunogen
featur
target
pathogen
addit
gener
antigen
depot
enhanc
adjuvant
nanoparticl
also
contribut
enhanc
vaccin
efficaci
particul
antigen
present
effici
target
apc
pharmacokinet
characterist
nanoparticl
depend
intrins
properti
particl
particl
size
could
implic
apc
uptak
biodistribut
bioavail
smaller
particl
phagocytos
slower
larger
particl
contribut
better
distribut
rapid
dissolut
therefor
optim
nanoparticl
composit
size
shape
depend
diseas
target
applic
characterist
one
commonli
use
polymer
nanoparticl
poli
lacticcoglycol
acid
plga
particl
biodegrad
polym
tailor
vari
degrad
releas
wide
rang
plgabas
drug
deliveri
system
use
treatment
diagnosi
mani
diseas
disord
mani
differ
fabric
process
util
produc
plga
base
nanocarri
print
particl
replic
nonwet
templat
process
stand
capac
control
particl
paramet
print
process
creat
monodispers
particl
uniform
shape
size
scalabl
process
use
encapsul
decor
hydrophil
hydrophob
biolog
cargo
describ
result
studi
assess
cation
print
plga
nanoparticl
differ
size
shape
platform
deliveri
eprotein
srece
antigen
base
vaccin
demonstr
print
nanoparticl
adsorb
srece
maintain
site
vaccin
within
drain
lymph
node
effici
solubl
antigen
adsorb
antigen
also
induc
higher
igg
titer
specif
neutral
antibodi
solubl
antigen
vero
cell
maintain
monolay
cell
cultur
co
dmem
gibco
media
supplement
nonessenti
amino
acid
uml
penicillin
streptomycin
fetal
bovin
serum
fb
lower
infect
use
product
srece
maintain
suspens
cultur
express
medium
life
technolog
cultur
passag
cellsml
cell
densiti
cellsml
reach
viru
strain
use
present
studi
determin
antibodi
titer
neutral
assay
solubl
recombin
envelop
protein
srece
express
use
transient
express
system
thermofish
use
manufactur
suppli
protocol
ntermin
secret
leader
peptid
fuse
prmsrece
cassett
srece
equip
ctermin
histidin
purif
tag
sequenc
ssggshhhhhh
express
driven
cag
cmv
earli
enhanc
actin
promot
supernat
concentr
buffer
exchang
ni
bind
buffer
napo
nacl
imidazol
naazid
via
tangenti
flow
filtrat
subject
ni
affin
chromatographi
wash
ni
bind
buffer
ni
column
step
elut
elut
buffer
napo
nacl
imidazol
naazid
glycerol
fraction
contain
envelop
protein
pool
concentr
subject
size
exclus
chromatographi
use
superdex
column
equilibr
pb
contain
glycerol
fraction
envelop
protein
pool
concentr
flash
frozen
liquid
n
store
result
envelop
protein
pure
assess
sdspage
purifi
srece
protein
fraction
subject
sodium
dodecyl
sulphat
polyacrylamid
gel
electrophoresi
sdspage
analyz
western
blot
wb
coomassi
brilliant
blue
cbb
stain
ng
srece
resuspend
denatur
gel
load
buffer
contain
sd
follow
electrophoresi
protein
transfer
nitrocellulos
membran
block
skim
milk
tb
hr
rt
next
membran
subject
mab
block
buffer
hr
membran
wash
time
block
buffer
treat
hrpconjug
antimous
igg
block
buffer
hr
wash
membran
develop
use
ecl
prime
western
blot
detect
reagent
amersham
srece
antigen
captur
elisa
assess
protein
conform
ni
coat
plate
pierc
coat
srece
tb
buffer
mm
tri
mm
nacl
ph
hr
plate
wash
block
wash
buffer
skim
milk
hr
block
buffer
discard
plate
incub
ngwell
indic
mousederiv
humanderiv
mab
block
buffer
hr
incub
plate
wash
treat
alkalin
phosphatas
ap
conjug
igg
sigma
igg
sigma
block
buffer
min
plate
subsequ
wash
develop
use
apsubstr
sigma
absorb
measur
nm
print
technolog
employ
manufactur
monodispers
plga
kda
lakeshor
biomateri
particl
previous
publish
briefli
plga
dccholesterol
avanti
polar
lipid
dissolv
chloroform
weight
ratio
cast
thin
film
petsheet
kr
plastic
film
place
contact
pattern
side
mold
pass
heat
nip
cheminstru
hot
roll
lamin
film
split
fill
mold
place
second
petsheet
subsequ
pass
lamin
transfer
particl
mold
petsheet
next
petsheet
incub
water
supplement
wt
polyvinyl
alcohol
pvoh
harvest
particl
particl
suspens
steril
use
polyeth
sulfon
membran
millipor
purifi
tangenti
flow
filtrat
polysulfon
hollow
fiber
membran
spectrum
laboratori
size
zpotenti
measur
conduct
plga
particl
dispers
mm
kcl
solut
use
zetas
nano
zs
particl
analyz
malvern
instrument
tabl
particl
concentr
determin
thermogravimetr
analysi
tga
ta
instrument
actual
load
level
dccholesterol
determin
revers
phase
highperform
liquid
chromatographi
hplc
evapor
light
scatter
detector
elsd
srece
adsorpt
plga
particl
srece
theoret
pi
incub
np
indic
ratio
min
rt
polyvinyl
alcohol
pvoh
water
particl
pellet
centrifug
min
g
amount
residu
solubl
protein
determin
quantiit
protein
assay
kit
life
technolog
follow
manufactur
instruct
immun
mice
formul
also
contain
sucros
isoton
ph
discharg
copper
mesh
formvar
carbon
coat
grid
ted
pella
inc
red
ca
usa
load
plga
particl
solut
min
rt
wash
time
milliq
water
grid
stain
sec
uranyl
acet
excess
uranyl
acet
remov
grid
airdri
rt
observ
leo
transmiss
electron
microscop
zeiss
femal
balbc
mice
purchas
jackson
laboratori
use
age
week
experi
involv
mice
carri
accord
anim
use
protocol
approv
univers
north
carolina
anim
care
use
committe
mice
euthan
co
follow
cervic
disloc
mice
immun
subcutan
flank
solubl
rece
n
alum
n
pb
vehicl
n
rece
adsorb
plgadcchol
n
per
size
nm
nm
nm
nm
particl
day
group
immun
antigen
dose
serum
sampl
collect
submandibular
bleed
day
elisa
plate
coat
ngwell
mab
mm
carbonatebicarbon
buffer
incub
overnight
next
day
plate
wash
wash
buffer
pb
block
block
buffer
wash
buffer
skim
milk
hr
next
plate
load
block
buffer
incub
hr
wash
immun
mice
sera
serial
dilut
block
buffer
load
plate
hr
plate
wash
subject
apconjug
igg
sigma
min
develop
wash
apsubstr
sigma
absorb
measur
nm
vehicl
group
use
determin
background
signal
assay
dilut
sera
experiment
group
reach
background
level
calcul
use
graphpad
prism
softwar
use
measur
end
point
dilut
titer
use
flow
cytometri
base
neutral
assay
measur
denv
neutral
antibodi
previous
describ
detail
brief
vero
cell
seed
cultur
plate
cellswel
incub
hr
mice
sera
serial
dilut
optimem
gibco
supplement
fb
appropri
amount
viru
establish
infect
determin
previous
ad
dilut
sera
incub
min
next
cell
wash
optimem
viru
incub
sera
ad
cell
hr
incub
cell
wash
growth
medium
incub
overnight
growth
medium
next
day
cell
wash
phosphat
buffer
salin
pb
treat
trypsin
gibco
min
detach
cell
resuspend
pb
transfer
new
roundbottom
cultur
plate
spun
rpm
min
cell
fix
paraformaldehyd
incub
min
room
temperatur
rt
next
permeabil
buffer
ad
fix
cell
spun
min
rpm
cell
wash
perm
buffer
spun
next
cell
block
permeabil
buffer
supplement
normal
mous
serum
min
rt
cell
subsequ
incub
alexa
fluor
conjug
antiprm
mab
dilut
block
buffer
hr
cell
wash
perm
buffer
final
resuspend
fac
buffer
percentag
infect
cell
determin
flow
cytometri
use
guava
flow
cytomet
emd
millipor
neutral
effici
sera
express
neut
valu
dilut
viru
neutral
calcul
use
graphpad
prism
softwar
rece
label
fluoresc
dye
alexa
fluor
use
alexa
fluor
protein
label
kit
life
technolog
lymphat
drainag
antigen
examin
previous
describ
mice
inject
subcutan
rear
right
footpad
recealexa
fluor
alon
adsorb
plga
particl
volum
mice
sacrif
hr
post
inject
drain
poplit
lymph
node
footpad
resect
imag
total
fluoresc
use
ivi
lumina
perkinelm
imag
system
excit
nm
emiss
filter
analysi
done
use
live
imag
softwar
version
bone
marrow
collect
mous
femur
tibia
previous
describ
erythrocyt
lyse
nh
cl
bone
marrow
cell
subsequ
cultur
cellsml
rpmi
gibco
supplement
fb
mm
lglutamin
uml
penicillin
streptomycin
ngml
ngml
granulocytemacrophagecoloni
stimul
factor
gmcsf
cultur
medium
replac
fresh
medium
day
bmdc
harvest
day
purifi
optiprep
densiti
medium
sigma
remov
dead
cell
test
cellular
uptak
antigen
recealexa
fluor
mix
plga
particl
h
incub
room
temperatur
min
complet
growth
medium
rpmi
fb
ad
day
purifi
bmdc
dose
sampl
hr
cell
wash
twice
pb
fix
paraformaldehyd
min
rt
next
cell
stain
dapi
min
room
temperatur
cell
wash
mount
fluorsav
emd
millipor
examin
zeiss
confoc
microscop
zeiss
full
prm
sequenc
ectodomain
e
ctermin
histidin
tag
clone
downstream
leader
sequenc
fig
pahexpress
vector
secret
rece
srece
produc
cell
purifi
supernat
use
hisaffin
chromatographi
analysi
final
product
coomassi
brilliant
blue
cbb
stain
western
blot
wb
detect
mous
mab
show
high
yield
purifi
recombin
protein
fig
srece
slightli
lower
molecular
weight
expect
size
full
length
wildtyp
eprotein
control
contain
membran
proxim
integr
region
protein
analyz
srece
structur
epitop
access
tag
protein
load
ni
coat
elisa
plate
detect
use
panel
wellcharacter
denv
mab
mous
deriv
human
deriv
test
reactiv
mab
tabl
abl
bind
srece
fig
denvcomplex
reactiv
envelop
domain
ii
edii
fusion
loop
bind
mab
envelop
domain
iii
ediii
bind
mab
bound
srece
highli
neutral
specif
human
mab
bind
e
protein
dimer
depend
quaternari
epitop
show
weak
bind
indic
small
fraction
protein
may
present
eprotein
homodim
typespecif
mab
use
neg
control
result
demonstr
srece
pure
display
conform
epitop
present
monom
four
differ
size
plga
nanoparticl
nm
nm
nm
nm
produc
use
print
technolog
analyz
transmiss
electron
microscopi
tem
fig
tem
imag
show
monodispers
particl
distribut
particl
size
adsorb
srece
plga
nanoparticl
variabl
sreceplga
ww
ratio
mix
togeth
minut
rt
keep
amount
srece
constant
decreas
particl
amount
obtain
higher
sreceplga
ratio
adsorpt
effici
determin
amount
nonadsorb
srece
spin
particl
fig
ww
ratio
result
nearli
adsorpt
effici
particl
size
decreas
adsorpt
effici
increas
ww
ratio
like
caus
excess
srece
avail
particl
surfac
mice
immun
subcutan
srece
rece
adsorb
nanoparticl
indic
size
anim
boost
twice
day
serum
sampl
taken
day
specif
end
point
dilut
epd
igg
titer
determin
day
day
one
week
post
second
boost
nm
nm
nm
plgarec
particl
induc
signific
higher
specif
igg
titer
compar
srece
fig
igg
titer
induc
nm
particl
adjuv
srece
alum
similar
induc
srece
gener
igg
titer
peak
day
remain
elev
day
fig
neutral
activ
sera
collect
day
day
determin
verocel
base
neutral
assay
express
dilut
neut
viru
neutral
antibodi
sera
mice
immun
srece
induc
mild
neutral
antibodi
respons
increas
addit
alum
day
fig
plga
particl
decor
srece
induc
signific
higher
neutral
antibodi
titer
solubl
srece
plga
group
show
differ
individu
anim
group
averag
order
magnitud
particul
group
high
level
neutral
antibodi
nanoparticl
vaccin
anim
maintain
day
fig
week
post
nd
boost
result
demonstr
srece
adsorb
onto
print
nanoparticl
induc
durabl
neutral
antibodi
significantli
higher
level
maintain
anim
receiv
solubl
antigen
alon
srece
induc
specif
neutral
antibodi
respons
immun
sera
analyz
abil
neutral
three
denv
serotyp
fig
although
induc
igg
respons
show
mild
crossreact
fig
neutral
antibodi
respons
strictli
direct
show
poor
crossneutr
denv
serotyp
monitor
antigen
vaccin
anim
estim
bioavail
effici
traffick
lymph
node
srece
fluoresc
label
subsequ
adsorb
plga
particl
indic
time
point
post
footpad
inocul
drain
poplit
lymphnod
pln
isol
analyz
presenc
antigen
fig
similar
rapid
initi
drainag
antigen
observ
srece
particleadsorb
rece
hr
post
inject
howev
pln
mice
inocul
srece
monosubunit
clearli
detect
hr
yet
undetect
hr
post
inocul
adsorpt
srece
plga
particl
regardless
size
shape
clearli
increas
bioavail
pln
sinc
antigen
still
detect
post
inocul
analysi
inocul
site
show
correspond
antigen
presenc
rel
differ
group
fig
particul
srece
detect
longer
footpad
compar
solubl
counterpart
yearli
million
peopl
infect
denv
million
symptomat
million
develop
sever
diseas
result
death
sever
group
perform
clinic
trial
tvlive
attenu
dengu
vaccin
lead
candid
lower
efficaci
serotyp
also
overal
poor
efficaci
young
children
highlight
import
explor
new
vaccin
platform
use
nanotechnolog
vaccin
develop
taken
rise
recent
decad
instead
use
whole
live
viru
formul
induc
immunolog
protect
infecti
diseas
subunit
subvir
particl
base
platform
provid
eleg
safe
altern
proven
efficaci
larg
varieti
viral
pathogen
studi
explor
use
plga
nanoparticl
decor
e
protein
subunit
print
produc
plga
nanoparticl
outperform
nanoparticl
product
system
emuls
nanoprecipit
spraydri
control
particl
shape
size
uniform
denv
protein
larg
membraneinterfac
glycoprotein
regul
receptor
recognit
viral
fusion
addit
major
antigen
determin
develop
potent
neutral
antibodi
respons
purifi
srece
antigen
display
conform
epitop
edii
ediii
target
human
mous
mab
human
mab
bind
quaternari
structur
epitop
display
e
protein
homodim
mab
bound
weakli
srece
demonstr
format
srece
dimer
immun
plgarec
result
higher
denv
igg
titer
specif
neutral
antibodi
anim
vaccin
solubl
antigen
alon
day
last
time
point
test
level
neutral
antibodi
induc
plgarec
compar
adjuv
srece
case
plga
particl
superior
adjuv
srece
inclus
adjuv
success
studi
reveal
extend
augment
plgacarri
capabl
previou
studi
demonstr
size
shape
nanocarri
influenc
process
cellular
uptak
transport
howev
observ
signific
effect
plga
particl
size
shape
denv
e
specif
antibodi
respons
observ
trend
x
nm
particl
induc
higher
level
bind
antibodi
x
nm
particl
induc
higher
level
neutral
antibodi
although
studi
need
precis
determin
effect
particl
properti
denv
immunogen
peopl
expos
primari
denv
infect
monoval
vaccin
serotypespecif
neutral
antibodi
implic
durabl
protect
immun
therefor
character
specif
neutral
antibodi
respons
monoval
vaccin
antigen
regardless
particl
shape
size
plgarec
induc
neutral
antibodi
mainli
specif
indic
neutral
respons
target
uniqu
epitop
next
directli
test
efficaci
pga
vaccin
mous
model
denv
infect
diseas
followup
challeng
studi
look
close
properti
neutral
antibodi
epitop
specif
antibodi
affin
igg
isotyp
also
analyz
breadth
respons
test
differ
genotyp
neutral
vaccin
studi
also
plan
test
tetraval
mixtur
plgarec
use
induc
balanc
typespecif
neutral
respons
serotyp
better
understand
mechan
respons
increas
immunogen
plga
group
analyz
antigen
uptak
mous
bone
marrow
deriv
dendrit
cell
bmdc
follow
drainag
antigen
footpad
inocul
site
pln
vitro
srece
plga
adsorb
rece
readili
taken
bmdc
fig
indic
uptak
antigen
present
cell
unlik
respons
enhanc
immunogen
plga
vaccin
plga
adsorb
srece
detect
site
vaccin
drain
lymph
node
much
longer
srece
alon
indic
extend
bioavail
like
respons
enhanc
antibodi
respons
plga
vaccin
anim
propos
plga
vaccin
lead
format
antigen
depot
inocul
site
gradual
releas
antigen
wherea
solubl
antigen
alon
effici
clear
vaccin
studi
show
print
produc
plga
particl
decor
srece
effect
platform
increas
immun
respons
target
srece
even
absenc
adjuv
use
strategi
abl
induc
long
last
serotyp
specif
neutral
antibodi
respons
increas
bioavail
antigen
clearli
show
ad
effect
particul
rais
immun
respons
antigen
traffick
though
focus
find
form
basi
studi
toward
serotyp
might
form
basi
safe
efficaci
dengu
viru
candid
addit
platform
use
develop
safe
vaccin
candid
flavivirus
zika
viru
pregnant
women
target
group
vaccin
support
inform
tabl
physicochem
character
plga
particl
print
produc
plga
nanoparticl
indic
size
examin
nano
zetas
dynam
light
scatter
dl
poli
dispers
index
pdi
zeta
potenti
